ALLO - Allogene receives IND clearance from FDA for ALLO-715 nirogacestat combination

Allogene Therapeutics ([[ALLO]] +0.0%) announced that the U.S. FDA has cleared an Investigational New Drug application to study ALLO-715 in combination with nirogacestat, SpringWorks Therapeutics’ investigational gamma secretase inhibitor, in patients with relapsed or refractory multiple myeloma.This combination represents one of Allogene’s three strategies to target BCMA for multiple myeloma and will be deployed in the ongoing UNIVERSAL trial.Enrollment in this cohort is expected to begin in Q1 2021.Multiple myeloma is the 2nd most common hematological malignancy in the U.S, with 32,270 new cases and 12,830 deaths estimated in 2020.“We look forward to investigating this combination as part of our comprehensive anti-BCMA strategy aimed at optimizing cell therapy for patients with relapsed/refractory multiple myeloma.” said Rafael Amado, M.D., Executive VP of R&D and Chief Medical Officer.

For further details see:

Allogene receives IND clearance from FDA for ALLO-715, nirogacestat combination